36301
document
Effect of ranitidine on the disposition of orally and intravenously administered triazolam . The effect of orally administered ranitidine on the pharmacokinetic properties of orally and intravenously administered triazolam was determined . Twelve healthy males with a mean age of 35 years were enrolled in this four-way , randomized , crossover study . Each subject received a total of four treatments , each separated by one week . The treatments consisted of ( 1 ) one orally administered 0.25-mg triazolam tablet after treatment with ranitidine ; ( 2 ) one orally administered 0.25-mg triazolam tablet , with no ranitidine pretreatment ; ( 3 ) a 0.25-mg intravenous dose of triazolam after treatment with ranitidine ; and ( 4 ) a 0.25-mg intravenous dose of triazolam , with no ranitidine pretreatment . Ranitidine pretreatment consisted of five 150-mg oral doses ( as the hydrochloride salt ) given every 12 hours ; the last dose was given two hours before triazolam was administered . Blood samples were taken at intervals up to 12 hours after triazolam treatment . Serum triazolam concentrations were measured by modified high-performance liquid chromatography , and pharmacokinetic values were calculated . Pretreatment with ranitidine had no effect on the disposition of intravenously administered triazolam but significantly increased the area under the serum drug concentration-time curve of oral triazolam . Ranitidine pretreatment had no effect on triazolam 's terminal elimination rate constant or on the time to reach maximum serum triazolam concentration . Ranitidine pretreatment increased the systemic availability of triazolam by increasing its absorption .
36302
Intervention_Pharmacological
ranitidine
36303
Intervention_Pharmacological
ranitidine
36304
Intervention_Pharmacological
triazolam
36305
Intervention_Pharmacological
0.25-mg triazolam tablet after treatment with ranitidine
36306
Intervention_Pharmacological
0.25-mg triazolam tablet , with no ranitidine pretreatment
36307
Intervention_Pharmacological
0.25-mg intravenous dose of triazolam after treatment with ranitidine
36308
Intervention_Pharmacological
0.25-mg intravenous dose of triazolam , with no ranitidine pretreatment
36309
Intervention_Pharmacological
Ranitidine
36310
Intervention_Pharmacological
triazolam
36311
Intervention_Pharmacological
triazolam
36312
Intervention_Pharmacological
ranitidine
36313
Intervention_Pharmacological
Ranitidine
36314
Intervention_Pharmacological
triazolam 's
36315
Intervention_Pharmacological
Ranitidine
36316
Intervention_Pharmacological
triazolam
36317
Outcome_Other
disposition
36318
Outcome_Physical
pharmacokinetic properties
36319
Outcome_Physical
Serum triazolam concentrations
36320
Outcome_Physical
pharmacokinetic values
36321
Outcome_Physical
disposition of intravenously administered triazolam
36322
Outcome_Physical
area under the serum drug concentration-time curve of oral triazolam .
36323
Outcome_Physical
triazolam 's terminal elimination rate constant
36324
Outcome_Physical
time to reach maximum serum triazolam concentration .
36325
Outcome_Physical
systemic availability of triazolam
36326
Outcome_Physical
absorption .
36327
Participant_Age
Twelve healthy males with a mean age of 35 years